These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Rare diseases: "a public health priorty". Interview by Catherine Holué]. Podeur A Rev Prat; 2012 Jan; 62(1):79-80. PubMed ID: 22335073 [No Abstract] [Full Text] [Related]
3. The challenges of orphan drugs and orphan diseases: real and imagined. Hudson I; Breckenridge A Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659 [TBL] [Abstract][Full Text] [Related]
4. [Rare diseases, a public health issue]. Donnart A; Viollet V; Roinet-Tournay M Soins Pediatr Pueric; 2013; (274):17-9. PubMed ID: 24228329 [TBL] [Abstract][Full Text] [Related]
6. [Orphan diseases, rare diseases, time to get mobilised]. Cordier JF Rev Prat; 2006 Jan; 56(2):123-4. PubMed ID: 16584035 [No Abstract] [Full Text] [Related]
7. Solutions to the R&D crisis for neglected diseases. Lancet; 2008 Nov; 372(9652):1784. PubMed ID: 19027471 [No Abstract] [Full Text] [Related]
8. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy. Liu BC; He L; He G; He Y J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648 [TBL] [Abstract][Full Text] [Related]
9. [Documentary research and self-instruction. Critical reading of a medical article. Practice guidelines. Part 1: rare diseases]. Cordier JF; Aymé S Rev Prat; 2004 Apr; 54(7):777-9. PubMed ID: 15253297 [No Abstract] [Full Text] [Related]
10. [Orphan drugs: availability, reliability and reimbursement]. Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041 [TBL] [Abstract][Full Text] [Related]
11. [Closing conference of the 1st day: Fighting against rare diseases: a priority for Eurobiomed, Biocluster of Southern, France]. Berthe J; Fourcade B; Pastor G; Le Dain AY; Kremp O Presse Med; 2012 May; 41 Suppl 1():S20-2. PubMed ID: 22480853 [No Abstract] [Full Text] [Related]
12. [Health technology assessment in the field of rare diseases at Haute Autorité de Santé in France]. Bélorgey C Med Sci (Paris); 2018 May; 34 Hors série n°1():49-50. PubMed ID: 29911564 [No Abstract] [Full Text] [Related]
13. [Rare diseases: an "exceptional field of research. Interview by Catherine Holué]. Dolfus H; Lévy N Rev Prat; 2012 Jan; 62(1):89-90. PubMed ID: 22335076 [No Abstract] [Full Text] [Related]
14. Issues surrounding orphan disease and orphan drug policies in Europe. Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226 [TBL] [Abstract][Full Text] [Related]
15. Health care policy. Reforming off-label promotion to enhance orphan disease treatment. Liang BA; Mackey T Science; 2010 Jan; 327(5963):273-4. PubMed ID: 20075234 [No Abstract] [Full Text] [Related]
16. [Cohorts and registers: Which public/private partnerships to choose?]. Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892 [No Abstract] [Full Text] [Related]